Measuring an Overlooked Outcome
In Alzheimer’s disease, decline rarely belongs to one person alone. It changes the household. A spouse becomes a medication manager. An adult child becomes a scheduler, advocate, driver, financial monitor, and emotional anchor. The work is intimate, constant, and often invisible.
That invisibility is beginning to matter scientifically.
For decades, Alzheimer’s clinical trials have focused on cognition, function, safety, and, more recently, biomarkers such as amyloid and tau. These measures remain essential. But researchers are increasingly recognizing that the value of a treatment cannot be understood fully unless it also considers the person providing daily care.
The Alzheimer’s Association’s 2026 Alzheimer’s Disease Facts and Figures report estimates that more than 7 million Americans are living with Alzheimer’s disease, with nearly 13 million unpaid caregivers providing support. That scale makes caregiver burden more than a private hardship. It’s a public health outcome.
Most Alzheimer’s trials already rely on caregivers. A knowledgeable study partner often helps report changes in memory, judgment, daily function, medication use, and safety. The Clinical Dementia Rating–Sum of Boxes, or CDR-SB, one of the field’s most widely used tools, incorporates information from both the patient and a reliable informant, often a spouse, adult child, or close care partner.
But caregiver input about the patient is not the same as measuring caregiver burden.
A caregiver may be asked whether a loved one is forgetting appointments, while no one asks whether the caregiver is sleeping, missing work, feeling isolated, or grieving the gradual loss of the relationship as it once was. That distinction matters. Caregivers have long served as observers in Alzheimer’s research. Only more recently have they begun to be treated as people with measurable outcomes of their own.
A 2021 review of dementia drug trials found that very few studies measured how treatment affected caregivers. When they did, researchers most often used the Zarit Burden Interview, a questionnaire that asks about the emotional, physical, and social strain of caregiving. Some studies also measured how distressed caregivers felt by dementia-related behavior changes, such as agitation, anxiety, or sleep disruption.
Caregiver burden is not a vague or sentimental concept. It is measurable. It includes emotional strain, social restriction, physical fatigue, financial pressure, anxiety, role changes, and grief.
August is National Grief Awareness Month and it offers a timely reminder that dementia caregiving often includes grief before death. The Alzheimer’s Association describes grief and loss as common experiences for caregivers, sometimes beginning at diagnosis and recurring as the disease changes personality, independence, and shared roles. The Family Caregiver Alliance, drawing on the work of family therapist and researcher Pauline Boss, describes dementia caregiving through the lens of “ambiguous loss” — or the painful experience of someone being physically present but psychologically changed.
This grief is not incidental. Research in dementia caregiving has linked anticipatory grief with psychological distress, including depressive symptoms. The U.S. Food and Drug Administration’s patient-focused drug development efforts have also emphasized the importance of systematically collecting patient and caregiver input when evaluating medical products.
One notable example came from the phase 3 Clarity AD trial of lecanemab in early Alzheimer’s disease. In exploratory quality-of-life analyses published in The Journal of Prevention of Alzheimer’s Disease, investigators reported that lecanemab was associated with less increase in care partner burden over 18 months compared with placebo, as measured by the Zarit Burden Interview.
That finding should be interpreted carefully. Not every treatment that slows decline will reduce caregiver burden. Some therapies may ease disease-related burden while adding treatment-related burden through infusions, monitoring, travel, cost, or anxiety about side effects. Future trials will need to distinguish among disease burden, caregiving workload, emotional burden, treatment burden, and the positive dimensions of caregiving, such as purpose, closeness, and love.
Clinicians do not need to wait for trial design to evolve. A brief caregiver check-in can be as important as a medication review: Are you sleeping? How many hours of care are you providing? Are you missing your own medical appointments? Because making a clinical trial more patient-centric means equipping and empowering the caregiver to remain healthy, supported, and able to sustain care.
To make it easy to get a memory screen, the Neuropsychiatric Research Center of Southwest Florida (NPRC) offers free memory screens at our office. To schedule your free memory screen, contact us at 239-939-7777. Please bring a list of your current medications to your appointment. The screening and all services provided at our center are at no cost to you and we do not ask for any insurance information. At the Neuropsychiatric Research center there are many cutting edge clinical studies that are focused on addressing memory issues. Take charge of your brain health and schedule your free memory screen today! #Memoriesmatter
Contact NPRC at 239-939-7777 today for your free memory screen.
Neuropsychiatric Research Center of Southwest Florida (NPRC)